Controlled Substances Market
Controlled Substances Market Analysis by Opioids, Stimulants, Depressants, and Marijuana for ADHD, Pain Management, Depression, Seizures, and Anxiety from 2023 to 2033
Analysis of Controlled Substances Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Controlled Substances Market Overview (2023 to 2033)
The global controlled substances market size is estimated at US$ 85.2 Billion in 2023, and is expected to attain a valuation of US$ 139 Billion by 2033-end, growing at a Compound Annual Growth Rate (CAGR) of 5% during the forecast period from 2023 to 2033.
Controlled substances are usually drugs whose manufacturing, distribution, and possession are regulated by governments as they may have the potential to cause addiction or result in substance abuse. Usually, controlled substances are distributed through prescriptions given out by medical professionals for the treatment of various mental and physical health disorders.
Storing controlled drugs illegally and distributing them without prescriptions could result in legal action in almost all countries around the world, with penalties varying from cash fines to imprisonment. The surging use of controlled substances to treat various medical conditions and their rising use in drug development and drug formulation procedures is also expected to boost market growth across the forecast period.
Rising number of people opting for medical marijuana over prescription drugs for the treatment of mental and physical health conditions is also projected to uplift shipments of controlled substances over the next ten years. Moreover, rising investments in medical research and development activities are also slated to benefit market development going forward.
Increasing prevalence of chronic health disorders, growing awareness regarding the benefits of controlled substances, rising demand for alternative medicine, and growing popularity of electronic prescriptions for controlled substances are also projected to incite market growth in the long run.
On the contrary, the soaring use of controlled substances in the manufacturing of illicit drugs and trafficking of controlled medications are major issues that are plaguing the medical industry for years and are projected to hamper controlled substance sales in the future.
- In May 2022, CVS Health Corp. and Walmart Inc., announced that they would stop selling prescriptions for controlled substances issued by telehealth start-ups such as Done Health and Cerebral Inc. Walmart stated that the decision was made after an audit and compliance process regarding the prescription of controlled substances.
An assessment expanding your knowledge on market influencing aspects such as supply chain management, local supply, product standards, safety regulations, and other market trends has been mentioned listed in this controlled substances market research survey by Fact.MR, a market research and competitive intelligence provider.
Report Attributes |
Details |
|
Market Size (2023) |
US$ 85.2 Billion |
|
Projected Market Value (2033F) |
US$ 139 Billion |
|
Global Market Growth Rate (2023 to 2033) |
5% CAGR |
|
Market Share of North America (2022) |
~35% |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Start-ups are Altering the Future of Controlled Substance Sales?
“Cerebral and Done Global Inc. to Crucially Influence Future of Controlled Substance Vendors”
Telehealth start-ups picked up traction with the advent of the global COVID-19 pandemic that started in early 2020 and online prescriptions were made legal in several countries. This trend continued even after the pandemic situation subsided and this create an opportune scenario for new companies to roll out their telehealth and online consultation services.
- Cerebral, a mental health start-up founded in 2019, was being investigated by the United States Department of Justice for the prescription of controlled substances such as Xanax and Adderall. The company offers therapy and prescribes treatment for conditions such as insomnia, ADHD, anxiety, etc. The investigation is an ongoing affair since 2022 and also resulted in the company halting the issuing of prescriptions for controlled medications for its new patients.
- In September 2022, reports were surfacing that the Drug Enforcement Administration’s Diversion Control Division is investigating Done Global Inc., a virtual ADHD medication management start-up. However, a company official came out and stated that the company had not received any notification from the DEA or any other federal organization for the same.
The crackdown on telehealth and virtual health start-ups that began with Cerebral is now affecting demand and sales of controlled substances around the world. Adderall is a major controlled substance that has been causing issues since it has the potential for drug abuse and possible dependence.
Federal laws and regulatory mandates surrounding the distribution and use of controlled substances are anticipated to create obstacles for incoming controlled substance providers and also hamper the business potential of established controlled substance companies.
Country-wise Insights
How is the Market for Controlled Substances Faring in the United States?
“Surging Use of Controlled Substances for Treatment of Diseases”
The use of controlled substances is relatively high in the United States as compared to most of the other countries in the world. Being a leader in pharmaceutical manufacturing and having a robust healthcare infrastructure has made the country a highly attractive market for controlled substance manufacturers and suppliers alike.
Rising number of patients using opioids and other controlled medications for the treatment of several health conditions is also projected to open up new avenues of opportunity for controlled substance companies in the United States going forward. Moreover, the legalization of medical marijuana in several states of the country is also expected to uplift market development across the forecast period.
On the flip side, the presence of controlled medication trafficking and substance abuse problems in American society is expected to foil controlled substance shipments in the future.
Why Should Controlled Substance Producers Invest in Japan?
“Expanding Senescent Population and Rising Focus on Healthcare”
Investments in healthcare infrastructure development have been increasing in Japan just like most other Asian countries in the region and this is creating moneymaking opportunities for controlled substance suppliers. The Japanese government is taking steps to strengthen its healthcare infrastructure which has been under pressure owing to the rising aging population in the country.
Growing prevalence of cancer and other chronic diseases is also a factor that is projected to promulgate sales of controlled substances in Japan over the next ten years. Drug pricing in the country is controlled by its government and this is also a key factor that could alter the demand for controlled substances across the forecast period in Japan. The rising popularity of generic medications in Japan could pave the way for new drugs and medications formulated using controlled substances.
Why Could European Countries Witness High Demand for Controlled Substances in the Future?
“Germany, France, & United Kingdom to Lead Product Demand in Europe”
The approval process for new drug formulations and medications has been changing in several European countries and this is projected to uplift the demand for controlled substances in Europe going forward. Furthermore, the relaxation of prescription policies in European countries is also anticipated to promulgate sales of controlled substances over the next ten years.
Increasing geriatric population, rising investments from public and private sectors in medical R&D, rising healthcare expenditure, growing demand for alternative medicines, surging prevalence of chronic disorders, and increasing use of controlled medications for the treatment of chronic diseases are other factors that influence shipments of controlled substances in countries such as Germany, France, Italy, and the United Kingdom.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Which Drug Class Accounts for a Commanding Market Share?
“Opioids Leading Global Market Growth”
Based on drug class, the market for controlled substances is segmented into opioids, depressants, stimulants, and marijuana.
Opioids account for a substantial share of the global controlled substances marketplace at present and are estimated to maintain a similar stance throughout the forecast period. They are extensively used in cancer treatment as they have pain-relieving abilities. The growing incidence of different types of cancers around the world is expected to boost the demand for opioids over the next ten years.
But the use of opioids is expected to be reduced in the long term owing its addiction issues that are increasing among patients around the world. Substance abuse through opioid drugs is a concerning factor that is projected to hamper sales of opioids across the forecast period.
Competitive Landscape
Prime controlled substance manufacturers are focusing on launching new products that help them maximize their business potential and gain a competitive advantage over other market players.
- In February 2023, Eighty Six, a provider of products derived from cannabinoids, announced its entry into the legal psychedelics marketplace with the launch of its new gummies under the name Fun Guy. The gummies are made from Amanita mushrooms that are legal through a loophole in all states of the United States except Louisiana.
More insights about new developments by leading controlled substance vendors and how they alter future pricing trends and product standards have been extensively discussed in this Fact.MR research survey.
Key Segments of Controlled Substances Industry Research
-
By Drug Class :
- Opioids
- Codeine
- Morphine
- Fentanyl
- Meperidine
- Methadone
- Oxycodone
- Others
- Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Methamphetamine
- Others
- Depressants
- Barbiturates
- Benzodiazepines
- Marijuana
- Medical Marijuana
- Recreational Marijuana
- Opioids
-
By Application :
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Pain Management
- Depression
- Seizure
- Anxiety
- Sleep Disorders
- Cough Suppression
- Others
-
By Distribution Channel :
- Institutional Sales
- Hospitals
- Clinics
- Rehabilitation Centers
- Retail Sales
- Retail Pharmacies
- e-Commerce/Mail Order Pharmacies
- Institutional Sales
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Technology Roadmap 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market, By Region 3.2. Key Promotional Strategies, By Manufacturers 4. Key Success Factors 4.1. Regulatory Scenario 4.2. Drug Abuse Epidemiology 4.3. Drug Abuse Statistics, U.S. 4.4. Drug Abuse Statistics, European Union 4.5. Pipeline Assessment 4.6. Medical Marijuana Patent Filings 4.7. Marijuana Statistics 4.8. Medical Marijuana Market Value Chain Analysis and Regulatory Scenario 5. Global Market Demand (in Value or Size in US$ Mn) Analysis 2018-2022 and Forecast, 2023-2033 5.1. Historical Market Value (US$ Mn) Analysis, 2018-2022 5.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Market Background 6.1. Macro-Economic Factors 6.1.1. Global GDP Growth Outlook 6.1.2. Changing Government Policies 6.1.3. Reference Pricing 6.1.4. Healthy economic growth in Emerging Countries 6.1.5. Rise In Global Annual Disposable Income Per Capita 6.2. Forecast Factors - Relevance & Impact 6.2.1. Increasing Prevalence of Chronic Diseases 6.2.2. Legalization of Marijuana And Reach of CS to Unmet Regions 6.2.3. Rising Abuse 6.2.4. Extensive Network of Distribution Channels 6.2.5. Production Volume for Raw Materials, Like Opium and Marijuana 6.3. Market Dynamics 6.3.1. Drivers 6.3.2. Restraints 6.3.3. Opportunity 7. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Drug Class 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2018 - 2022 7.3. Current Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2023 - 2033 7.3.1. Opioids 7.3.1.1. Codeine 7.3.1.2. Morphine 7.3.1.3. Fentanyl 7.3.1.4. Meperidine 7.3.1.5. Methadone 7.3.1.6. Oxycodone 7.3.1.7. Others 7.3.2. Stimulants 7.3.2.1. Amphetamine 7.3.2.2. Methylphenidate 7.3.2.3. Dextroamphetamine 7.3.2.4. Methamphetamine 7.3.2.5. Others 7.3.3. Depressants 7.3.3.1. Barbiturates 7.3.3.2. Benzodiazepines 7.3.4. Marijuana 7.3.4.1. Medical Marijuana 7.3.4.2. Recreational Marijuana 7.4. Market Attractiveness Analysis By Drug Class 8. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Application 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Application, 2018 - 2022 8.3. Current Market Size (US$ Mn) Analysis and Forecast By Application, 2023 - 2033 8.3.1. Attention-Deficit/Hyperactivity Disorder (ADHD) 8.3.2. Pain Management 8.3.3. Depression 8.3.4. Seizure 8.3.5. Anxiety 8.3.6. Sleep Disorders 8.3.7. Cough Suppression 8.3.8. Others 8.4. Market Attractiveness Analysis By Application 9. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Distribution Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2018 - 2022 9.3. Current Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2023 - 2033 9.3.1. Institutional Sale 9.3.1.1. Hospitals 9.3.1.2. Clinics 9.3.1.3. Rehabilitation Centers 9.3.2. Retail Sales 9.3.2.1. Retail Pharmacies 9.3.2.2. E- Commerce/Mail Order Pharmacies 9.4. Market Attractiveness Analysis By Distribution Channel 10. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Region 10.1. Introduction 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2018 - 2022 10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023 - 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. Middle East and Africa (MEA) 10.3.5. East Asia 10.3.6. South Asia 10.3.7. Oceania 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2018-2022 and Forecast 2023-2033 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 - 2022 11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 - 2033 11.3.1. By Country 11.3.1.1. U.S. 11.3.1.2. Canada 11.3.2. By Drug Class 11.3.3. By Application 11.3.4. By Distribution Channel 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Drug Class 11.4.3. By Application 11.4.4. By Distribution Channel 11.5. Drivers and Restraints - Impact Analysis 12. Latin America Market Analysis 2018-2022 and Forecast 2023-2033 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 - 2022 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 - 2033 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Mexico 12.3.1.3. Rest of Latin America 12.3.2. By Drug Class 12.3.3. By Application 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Drug Class 12.4.3. By Application 12.4.4. By Distribution Channel 12.5. Drivers and Restraints - Impact Analysis 13. Europe Market Analysis 2018-2022 and Forecast 2023-2033 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 - 2022 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 - 2033 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. Italy 13.3.1.3. France 13.3.1.4. U.K. 13.3.1.5. Spain 13.3.1.6. BENELUX 13.3.1.7. Russia 13.3.1.8. Rest of Europe 13.3.2. By Drug Class 13.3.3. By Application 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Class 13.4.3. By Application 13.4.4. By Distribution Channel 13.5. Drivers and Restraints - Impact Analysis 14. South Asia Market Analysis 2018-2022 and Forecast 2023-2033 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 - 2022 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 - 2033 14.3.1. By Country 14.3.1.1. India 14.3.1.2. Thailand 14.3.1.3. Indonesia 14.3.1.4. Malaysia 14.3.1.5. Rest of South Asia 14.3.2. By Drug Class 14.3.3. By Application 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Class 14.4.3. By Application 14.4.4. By Distribution Channel 14.5. Drivers and Restraints - Impact Analysis 15. East Asia Market Analysis 2018-2022 and Forecast 2023-2033 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 - 2022 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 - 2033 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Drug Class 15.3.3. By Application 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Class 15.4.3. By Application 15.4.4. By Distribution Channel 15.5. Drivers and Restraints - Impact Analysis 16. Oceania Market Analysis 2018-2022 and Forecast 2023-2033 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 - 2022 16.3. Market Size (US$ Mn) and Forecast By Market Taxonomy, 2023 - 2033 16.3.1. By Country 16.3.1.1. Australia 16.3.1.2. New Zealand 16.3.2. By Drug Class 16.3.3. By Application 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Class 16.4.3. By Application 16.4.4. By Distribution Channel 16.5. Drivers and Restraints - Impact Analysis 17. Middle East and Africa Market Analysis 2018-2022 and Forecast 2023-2033 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018 - 2022 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023 - 2033 17.3.1. By Country 17.3.1.1. GCC Countries 17.3.1.2. Turkey 17.3.1.3. Northern Africa 17.3.1.4. South Africa 17.3.1.5. Rest of Middle East and Africa 17.3.2. By Drug Class 17.3.3. By Application 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Application 17.4.4. By Distribution Channel 17.5. Drivers and Restraints - Impact Analysis 18. Emerging Countries Market Analysis 2018-2022 and Forecast 2023-2033 18.1. Introduction 18.1.1. Market Value Proportion Analysis, By Key Countries 18.1.2. Global Vs. Country Growth Comparison 18.2. South Africa Market Analysis 18.2.1. Introduction 18.2.2. Market Value Proportion Analysis by Market Taxonomy 18.2.3. Value (US$ Mn) Analysis and Forecast by Market Taxonomy 18.2.3.1. By Drug Class 18.2.3.2. By Distribution Channel 18.2.3.3. By Application 18.2.4. South Africa Market- Competition Landscape 18.3. India Market Analysis 18.3.1. Introduction 18.3.2. Market Value Proportion Analysis by Market Taxonomy 18.3.3. Value (US$ Mn) Analysis and Forecast by Market Taxonomy 18.3.3.1. By Drug Class 18.3.3.2. By Distribution Channel 18.3.3.3. By Application 18.3.4. India Market- Competition Landscape 18.4. Brazil Market Analysis 18.4.1. Introduction 18.4.2. Market Value Proportion Analysis by Market Taxonomy 18.4.3. Value (US$ Mn) Analysis and Forecast by Market Taxonomy 18.4.3.1. By Drug Class 18.4.3.2. By Distribution Channel 18.4.3.3. By Application 18.4.4. Brazil Market- Competition Landscape 19. Competition Analysis 19.1. Competition Dashboard 19.2. Competition Deep Dive 19.2.1. Cambrex 19.2.1.1. Overview 19.2.1.2. Product Portfolio 19.2.1.3. Profitability by Market Segments (Product/Channel/Region) 19.2.1.4. Strategy Overview 19.2.2. Cambrex 19.2.2.1. Overview 19.2.2.2. Product Portfolio 19.2.2.3. Profitability by Market Segments (Product/Channel/Region) 19.2.2.4. Strategy Overview 19.2.3. Patheon 19.2.3.1. Overview 19.2.3.2. Product Portfolio 19.2.3.3. Profitability by Market Segments (Product/Channel/Region) 19.2.3.4. Strategy Overview 19.2.4. Consort Medical 19.2.4.1. Overview 19.2.4.2. Product Portfolio 19.2.4.3. Profitability by Market Segments (Product/Channel/Region) 19.2.4.4. Strategy Overview 19.2.5. Cayman Chemical 19.2.5.1. Overview 19.2.5.2. Product Portfolio 19.2.5.3. Profitability by Market Segments (Product/Channel/Region) 19.2.5.4. Strategy Overview 19.2.6. AMRI 19.2.6.1. Overview 19.2.6.2. Product Portfolio 19.2.6.3. Profitability by Market Segments (Product/Channel/Region) 19.2.6.4. Strategy Overview 19.2.7. Siegfried AG 19.2.7.1. Overview 19.2.7.2. Product Portfolio 19.2.7.3. Profitability by Market Segments (Product/Channel/Region) 19.2.7.4. Strategy Overview 19.2.8. Johnson Matthey 19.2.8.1. Overview 19.2.8.2. Product Portfolio 19.2.8.3. Profitability by Market Segments (Product/Channel/Region) 19.2.8.4. Strategy Overview 19.2.9. SAFC/Cerilliant 19.2.9.1. Overview 19.2.9.2. Product Portfolio 19.2.9.3. Profitability by Market Segments (Product/Channel/Region) 19.2.9.4. Strategy Overview 19.2.10. Noramco, Inc 19.2.10.1. Overview 19.2.10.2. Product Portfolio 19.2.10.3. Profitability by Market Segments (Product/Channel/Region) 19.2.10.4. Strategy Overview 19.2.11. Mallinckrodt plc 19.2.11.1. Overview 19.2.11.2. Product Portfolio 19.2.11.3. Profitability by Market Segments (Product/Channel/Region) 19.2.11.4. Strategy Overview 19.2.12. GlaxoSmithKline plc. 19.2.12.1. Overview 19.2.12.2. Product Portfolio 19.2.12.3. Profitability by Market Segments (Product/Channel/Region) 19.2.12.4. Strategy Overview 19.2.13. Purdue Pharma L.P. 19.2.13.1. Overview 19.2.13.2. Product Portfolio 19.2.13.3. Profitability by Market Segments (Product/Channel/Region) 19.2.13.4. Strategy Overview 19.2.14. Teva Pharmaceuticals, Inc. 19.2.14.1. Overview 19.2.14.2. Product Portfolio 19.2.14.3. Profitability by Market Segments (Product/Channel/Region) 19.2.14.4. Strategy Overview 19.2.15. Johnson & Johnson (Janssen) 19.2.15.1. Overview 19.2.15.2. Product Portfolio 19.2.15.3. Profitability by Market Segments (Product/Channel/Region) 19.2.15.4. Strategy Overview 19.2.16. Daiichi Sankyo Company 19.2.16.1. Overview 19.2.16.2. Product Portfolio 19.2.16.3. Profitability by Market Segments (Product/Channel/Region) 19.2.16.4. Strategy Overview 19.2.17. Akorn Inc 19.2.17.1. Overview 19.2.17.2. Product Portfolio 19.2.17.3. Profitability by Market Segments (Product/Channel/Region) 19.2.17.4. Strategy Overview 19.2.18. Pfizer Inc. 19.2.18.1. Overview 19.2.18.2. Product Portfolio 19.2.18.3. Profitability by Market Segments (Product/Channel/Region) 19.2.18.4. Strategy Overview 19.2.19. Takeda Pharmaceutical Company Limited 19.2.19.1. Overview 19.2.19.2. Product Portfolio 19.2.19.3. Profitability by Market Segments (Product/Channel/Region) 19.2.19.4. Strategy Overview 19.2.20. Mylan N.V. 19.2.20.1. Overview 19.2.20.2. Product Portfolio 19.2.20.3. Profitability by Market Segments (Product/Channel/Region) 19.2.20.4. Strategy Overview 19.2.21. Sun Pharmaceutical Industries Ltd 19.2.21.1. Overview 19.2.21.2. Product Portfolio 19.2.21.3. Profitability by Market Segments (Product/Channel/Region) 19.2.21.4. Strategy Overview 19.2.22. Tilray 19.2.22.1. Overview 19.2.22.2. Product Portfolio 19.2.22.3. Profitability by Market Segments (Product/Channel/Region) 19.2.22.4. Strategy Overview 19.2.23. GW PHARMACEUTICALS PLC 19.2.23.1. Overview 19.2.23.2. Product Portfolio 19.2.23.3. Profitability by Market Segments (Product/Channel/Region) 19.2.23.4. Strategy Overview 19.2.24. Aphria Incorporation 19.2.24.1. Overview 19.2.24.2. Product Portfolio 19.2.24.3. Profitability by Market Segments (Product/Channel/Region) 19.2.24.4. Strategy Overview 19.2.25. Aurora Cannabis Inc 19.2.25.1. Overview 19.2.25.2. Product Portfolio 19.2.25.3. Profitability by Market Segments (Product/Channel/Region) 19.2.25.4. Strategy Overview 19.2.26. Canopy Growth Corporation 19.2.26.1. Overview 19.2.26.2. Product Portfolio 19.2.26.3. Profitability by Market Segments (Product/Channel/Region) 19.2.26.4. Strategy Overview 19.2.27. Insys Therapeutics, Inc. 19.2.27.1. Overview 19.2.27.2. Product Portfolio 19.2.27.3. Profitability by Market Segments (Product/Channel/Region) 19.2.27.4. Strategy Overview 19.2.28. Medical Marijuana, Inc. 19.2.28.1. Overview 19.2.28.2. Product Portfolio 19.2.28.3. Profitability by Market Segments (Product/Channel/Region) 19.2.28.4. Strategy Overview 19.2.29. The Peace Naturals Project 19.2.29.1. Overview 19.2.29.2. Product Portfolio 19.2.29.3. Profitability by Market Segments (Product/Channel/Region) 19.2.29.4. Strategy Overview 19.2.30. CANNABIS SATIVA, INC. 19.2.30.1. Overview 19.2.30.2. Product Portfolio 19.2.30.3. Profitability by Market Segments (Product/Channel/Region) 19.2.30.4. Strategy Overview 19.2.31. Green Relief Inc. 19.2.31.1. Overview 19.2.31.2. Product Portfolio 19.2.31.3. Profitability by Market Segments (Product/Channel/Region) 19.2.31.4. Strategy Overview 20. Assumptions and Acronyms Used 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Pipeline Assessment for Stimulants
Table 02: Expenditure on Health, (% of GDP), by Country, 2018–2022
Table 03: Expenditure on Health, (% of GDP), by Country, 2018–2022
Table 04: Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 05: Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 06: Global Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 07: Global Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 08: Global Market size (US$ Mn) Analysis 2013–2017 and Forecast 2018–2028 By Region
Table 09: North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 10: North America Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 11: North America Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 12: North America Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 13: North America Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 14: Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 15: Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 16: Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 17: Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 18: Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 19: Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 20: Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 21: Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 22: Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 23: Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 24: East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 25: East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 26: East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 27: East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 28: East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 29: South Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 30: South Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 31: South Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 32: South Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 33: South Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 34: Oceania Market Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 35: Oceania Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 36: Oceania Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 37: Oceania Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 38: Oceania Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 39: MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country
Table 40: MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 41: MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 42: MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 43: MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 44: Emerging Market Value Proportion Analysis 2018-2022 and Forecast 2023-2033, By Country vs Global value
Table 45: India Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 46: India Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 47: India Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 48: India Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 49: South Africa Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 50: South Africa Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 51: South Africa Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 52: South Africa Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
Table 53: Brazil Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 54: Brazil Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
Table 55: Brazil Market Analysis 2018-2022 and Forecast 2023-2033, By Application
Table 56: Brazil Market Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Pipeline Assessment For Opioids, By phase
Figure 02: Pipeline Assessment For Opioids, By Trial Status
Figure 03: Pipeline Assessment For Stimulants, By phase
Figure 04: Pipeline Assessment For Stimulants, By Trial Status
Figure 05: Medical Marijuana Patent Citations Analysis, 2018–2022, By Country
Figure 06: Medical Marijuana Patent Citations Analysis, from 2023–2033
Figure 07: Global Market Value Analysis and Forecast, 2018–2033 (US$ Mn)
Figure 08: Global Market Absolute $ Opportunity (US$ Mn), 2018–2022
Figure 09: Global Market Absolute $ Opportunity (US$ Mn), 2018–2033
Figure 10: Global Market Share%, by Drug Class, 2022E - Opioids
Figure 11: Global Market Share%, by Drug Class, 2022E - Stimulants
Figure 12: Global Market Share%, by Drug Class, 2022E - Depressants
Figure 13: Global Market Share%, by Drug Class, 2022E - Marijuana
Figure 14: Global Market Size (US$ Mn) Analysis, 2018–2022, by Opioids
Figure 15: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Opioids
Figure 16: Global Market Size (US$ Mn) Analysis, 2018–2022, by Stimulants
Figure 17: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Stimulants
Figure 18: Global Market Size (US$ Mn) Analysis, 2018–2022, by Depressants
Figure 19: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Depressants
Figure 20: Global Market Size (US$ Mn) Analysis, 2018–2022, by Marijuana
Figure 21: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Marijuana
Figure 22: Global Market Attractiveness Analysis, By Drug Class
Figure 23: Global Market Attractiveness Analysis, By Application
Figure 24: Global Market Attractiveness Analysis, By Distribution Channel
Figure 25: Global Market Incremental Opportunity US$, by Region, 2018-2033
Figure 26: Market Share%, by Region, 2022E
Figure 27: Global Market Absolute Opportunity US$, by Region, 2023-2033
Figure 28: Market Share%, by Region, 2033F
Figure 29: Global Market Attractiveness Analysis, By Region
Figure 30: North America Market size (US$ Mn) Analysis, 2018–2022
Figure 31: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 32: US Market Size (US$ Mn) Analysis, 2018–2022
Figure 33: US Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 34: Canada Market Size (US$ Mn) Analysis, 2018–2022
Figure 35: Canada Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 36: North America Market Size (US$ Mn) Analysis, 2018–2022, by Opioids
Figure 37: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Opioids
Figure 38: North America Market Size (US$ Mn) Analysis, 2018–2022, by Stimulants
Figure 39: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Stimulants
Figure 40: North America Market Size (US$ Mn) Analysis, 2018–2022, by Depressants
Figure 41: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Depressants
Figure 42: North America Market Size (US$ Mn) Analysis, 2018–2022, by Marijuana
Figure 43: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Marijuana
Figure 44: North America Market Attractiveness Analysis, By Drug Type
Figure 45: North America Market Attractiveness Analysis, By Application
Figure 46: North America Market Attractiveness Analysis, By Distribution Channel
Figure 47: North America Market Attractiveness Analysis, By Country
Figure 48: Latin America Market size (US$ Mn) Analysis, 2018–2022
Figure 49: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 50: Brazil Market Size (US$ Mn) Analysis, 2018–2022
Figure 51: Brazil Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 52: Mexico Market Size (US$ Mn) Analysis, 2018–2022
Figure 53: Mexico Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 54: Rest of Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 55: Rest of Latin America Market Size (US$ Mn) Analysis, 2018–2022
Figure 56: Latin America Market Size (US$ Mn) Analysis, 2018–2022, by Opioids
Figure 57: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Opioids
Figure 58: Latin America Market Size (US$ Mn) Analysis, 2018–2022, by Stimulants
Figure 59: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Stimulants
Figure 60: Latin America Market Size (US$ Mn) Analysis, 2018–2022, by Depressants
Figure 61: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Depressants
Figure 62: Latin America Market Size (US$ Mn) Analysis, 2018–2022, by Marijuana
Figure 63: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Marijuana
Figure 64: Latin America Market Attractiveness Analysis, By Drug Type
Figure 65: Latin America Market Attractiveness Analysis, By Application
Figure 66: Latin America Market Attractiveness Analysis, By Distribution Channel
Figure 67: Latin America Market Attractiveness Analysis, By Country
Figure 68: Europe Market size (US$ Mn) Analysis, 2018–2022
Figure 69: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 70: U.K. Market Size (US$ Mn) Analysis, 2018–2022
Figure 71: U.K. Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 72: Germany Market Size (US$ Mn) Analysis, 2018–2022
Figure 73: Germany Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 74: France Market Size (US$ Mn) Analysis, 2018–2022
Figure 75: France Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 76: Italy Market Size (US$ Mn) Analysis, 2018–2022
Figure 77: Italy Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 78: Spain Market Size (US$ Mn) Analysis, 2018–2022
Figure 79: Spain Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 80: BENELUX Market Size (US$ Mn) Analysis, 2018–2022
Figure 81: BENELUX Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 82: Russia Market Size (US$ Mn) Analysis, 2018–2022
Figure 83: Russia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 84: Rest of Europe Market Size (US$ Mn) Analysis, 2018–2022
Figure 85: Rest of Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 86: Europe Market Size (US$ Mn) Analysis, 2018–2022, by Opioids
Figure 87: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Opioids
Figure 88: Europe Market Size (US$ Mn) Analysis, 2018–2022, by Stimulants
Figure 89: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Stimulants
Figure 90: Europe Market Size (US$ Mn) Analysis, 2018–2022, by Depressants
Figure 91: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Depressants
Figure 92: Europe Market Size (US$ Mn) Analysis, 2018–2022, by Marijuana
Figure 93: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Marijuana
Figure 94: Europe Market Attractiveness Analysis, By Drug Type
Figure 95: Europe Market Attractiveness Analysis, By Application
Figure 96: Europe Market Attractiveness Analysis, By Distribution Channel
Figure 97: Europe Market Attractiveness Analysis, By Country
Figure 98: East Asia Market size (US$ Mn) Analysis, 2018–2022
Figure 99: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 100: China Market Size (US$ Mn) Analysis, 2018–2022
Figure 101: China Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 102: Japan Market Size (US$ Mn) Analysis, 2018–2022
Figure 103: Japan Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 104: South Korea Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 105: South Korea Market Size (US$ Mn) Analysis, 2018–2022
Figure 106: East Asia Market Size (US$ Mn) Analysis, 2018–2022, by Opioids
Figure 107: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Opioids
Figure 108: East Asia Market Size (US$ Mn) Analysis, 2018–2022, by Stimulants
Figure 109: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Stimulants
Figure 110: East Asia Market Size (US$ Mn) Analysis, 2018–2022, by Depressants
Figure 111: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Depressants
Figure 112: East Asia Market Size (US$ Mn) Analysis, 2018–2022, by Marijuana
Figure 113: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Marijuana
Figure 114: East Asia Market Attractiveness Analysis, By Drug Type
Figure 115: East Asia Market Attractiveness Analysis, By Application
Figure 116: East Asia Market Attractiveness Analysis, By Distribution Channel
Figure 117: East Asia Market Attractiveness Analysis, By Country
Figure 118: South Asia Market size (US$ Mn) Analysis, 2018–2022
Figure 119: Global Donor Egg IVF Market Attractiveness Analysis by Region , 2023-2033
Figure 119: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 120: India Market Size (US$ Mn) Analysis, 2018–2022
Figure 121: India Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 122: Thailand Market Size (US$ Mn) Analysis, 2018–2022
Figure 123: Thailand Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 124: Indonesia Market Size (US$ Mn) Analysis, 2018–2022
Figure 125: Indonesia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 126: Malaysia Market Size (US$ Mn) Analysis, 2018–2022
Figure 127: Malaysia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 128: Rest of South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 129: Rest of South Asia Market Size (US$ Mn) Analysis, 2018–2022
Figure 130: South Asia Market Size (US$ Mn) Analysis, 2018–2022, by Opioids
Figure 131: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Opioids
Figure 132: South Asia Market Size (US$ Mn) Analysis, 2018–2022, by Stimulants
Figure 133: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Stimulants
Figure 134: South Asia Market Size (US$ Mn) Analysis, 2018–2022, by Depressants
Figure 135: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Depressants
Figure 136: South Asia Market Size (US$ Mn) Analysis, 2018–2022, by Marijuana
Figure 137: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Marijuana
Figure 138: South Asia Market Attractiveness Analysis, By Drug Type
Figure 139: South Asia Market Attractiveness Analysis, By Application
Figure 140: South Asia Market Attractiveness Analysis, By Distribution Channel
Figure 141: South Asia Market Attractiveness Analysis, By Country
Figure 142: Oceania Market size (US$ Mn) Analysis, 2018–2022
Figure 143: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 144: Australia Market Size (US$ Mn) Analysis, 2018–2022
Figure 145: Australia Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 146: New Zealand Market Size (US$ Mn) Analysis, 2018–2022
Figure 147: New Zealand Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 148: Oceania Market Size (US$ Mn) Analysis, 2018–2022, by Opioids
Figure 149: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Opioids
Figure 150: Oceania Market Size (US$ Mn) Analysis, 2018–2022, by Stimulants
Figure 151: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Stimulants
Figure 152: Oceania Market Size (US$ Mn) Analysis, 2018–2022, by Depressants
Figure 153: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Depressants
Figure 154: Oceania Market Size (US$ Mn) Analysis, 2018–2022, by Marijuana
Figure 155: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Marijuana
Figure 156: Oceania Market Attractiveness Analysis, By Drug Type
Figure 157: Oceania Market Attractiveness Analysis, By Application
Figure 158: Oceania Market Attractiveness Analysis, By Distribution Channel
Figure 159: Oceania Market Attractiveness Analysis, By Country
Figure 160: MEA Market size (US$ Mn) Analysis, 2018–2022
Figure 161: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 162: South Africa Market Size (US$ Mn) Analysis, 2018–2022
Figure 163: South Africa Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 164: GCC Countries Market Size (US$ Mn) Analysis, 2018–2022
Figure 165: GCC Countries Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 166: Rest of MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 167: Rest of MEA Market Size (US$ Mn) Analysis, 2018–2022
Figure 168: MEA Market Size (US$ Mn) Analysis, 2018–2022, by Opioids
Figure 169: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Opioids
Figure 170: MEA Market Size (US$ Mn) Analysis, 2018–2022, by Stimulants
Figure 171: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Stimulants
Figure 172: MEA Market Size (US$ Mn) Analysis, 2018–2022, by Depressants
Figure 173: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Depressants
Figure 174: MEA Market Size (US$ Mn) Analysis, 2018–2022, by Marijuana
Figure 175: MEA Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033, by Marijuana
Figure 176: MEA Market Attractiveness Analysis, By Drug Type
Figure 177: MEA Market Attractiveness Analysis, By Application
Figure 178: MEA Market Attractiveness Analysis, By Distribution Channel
Figure 179: MEA Market Attractiveness Analysis, By Country
Figure 180: Market Value Proportion Analysis, By Key Countries, 2022E
Figure 181: Global Vs. Country, Y-O-Y Growth Comparison
Figure 182: India Market size (US$ Mn) Analysis, 2018–2022
Figure 183: India Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 184: India Market Attractiveness Analysis, By Drug Class
Figure 185: India Market Attractiveness Analysis, By Application
Figure 186: India Market Attractiveness Analysis, By Distribution Channel
Figure 187: South Africa Market size (US$ Mn) Analysis, 2018–2022
Figure 188: South Africa Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 189: South Africa Market Attractiveness Analysis, By Drug Class
Figure 190: South Africa Market Attractiveness Analysis, By Application
Figure 191: South Africa Market Attractiveness Analysis, By Distribution Channel
Figure 192: Brazil Market size (US$ Mn) Analysis, 2018–2022
Figure 193: Brazil Market Value (US$ Mn) & Y-o-Y Growth (%), 2023–2033
Figure 194: Brazil Market Attractiveness Analysis, By Drug Class
Figure 195: Brazil Market Attractiveness Analysis, By Application
Figure 196: Brazil Market Attractiveness Analysis, By Distribution Channel
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the total market worth of the controlled substances market?
The global controlled substances market is valued at US$ 85.2 billion in 2023.
What is the projected controlled substances market size for 2033?
Worldwide controlled substance sales are expected to reach US$ 139 billion by 2033-end.
What is the growth rate of the global controlled substances market?
From 2023 to 2033, consumption of controlled substances is expected to rise steadily at 5% CAGR.
What are the 4 types of controlled substances?
Opioids, depressants, stimulants, and marijuana are the types of controlled substances detailed in this report.
What are the driving factors of the controlled substances market?
Rising use of opioids in cancer treatment and increasing investments in medical research & development are key market drivers.
Who are the key players in the controlled substances market?
Johnson Matthey, Siegfried AG, Cayman Chemical, Consort Medical, and Patheon are leading suppliers of controlled substances.
Controlled Substances Market